scholarly journals Paradoxical effects of cyclosporin A on collagen arthritis in rats.

1983 ◽  
Vol 158 (6) ◽  
pp. 2007-2015 ◽  
Author(s):  
N Kaibara ◽  
T Hotokebuchi ◽  
K Takagishi ◽  
I Katsuki

The effect of the immunosuppressive agent cyclosporin A (CS-A) on collagen arthritis in Sprague-Dawley rats is investigated. A 14-d course of CS-A treatment at doses of 15 mg/kg per day or more, begun on the same day as type II collagen immunization, suppressed the development of arthritis as well as humoral and delayed-type hypersensitivity (DTH) skin test responses to type II collagen, possibly by interfering with helper T cells. Additional studies demonstrated that CS-A treatment only during the induction phase of immunity proved to be successful. When CS-A treatment was started only during the immediately preclinical phase of arthritis or after the disease onset, a significant enhancement of the disease was obtained in a dose-dependent manner. This enhancement was accompanied by an augmentation of DTH skin reactions, while antibody responses were either suppressed or unaffected. These results appear to be attributable at least in part to a suppressive effect of CS-A on a population of suppressor T cells, thus resulting in a T cell-mediated helper effect. It is therefore reasonable to assume that the paradoxical effects of CS-A on collagen arthritis in rats might be caused by an altering of the sensitive balance of the two regulatory subpopulations of T cells. It is also possible that cell-mediated immune responses may play an important role in influencing the course of the disease.

1985 ◽  
Vol 162 (5) ◽  
pp. 1531-1545 ◽  
Author(s):  
S M Helfgott ◽  
R Dynesius-Trentham ◽  
E Brahn ◽  
D E Trentham

A type II collagen-specific arthritogenic lymphokine has been identified in the rat. Arthritogenic factor (AF) is a 65 kD protein generated in vitro by T cells from rats with collagen arthritis, and it induces an erosive, proliferative synovitis when injected into the knee joint of syngeneic naive recipients. Complement does not appear to be required. These data identify a potential T cell-mediated effector mechanism in this model, and suggest that AF may function in other inflammatory synovial diseases.


2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Corina Peña ◽  
David Gárate ◽  
Juan Contreras-Levicoy ◽  
Octavio Aravena ◽  
Diego Catalán ◽  
...  

Background. Pharmacologically modulated dendritic cells (DCs) have been shown to restore tolerance in type II collagen-(CII-) induced arthritis (CIA). We examined the effect of dexamethasone (DXM) administration as a preconditioning agent, followed by an injection of lipopolysaccharide-(LPS-) stimulated and CII-loaded DCs on the CIA course.Methods. After CIA induction, mice pretreated with DXM were injected with 4-hour LPS-stimulated DCs loaded with CII (DXM/4hLPS/CII/DCs).Results. Mice injected with DXM/4hLPS/CII/DCs displayed significantly less severe clinical disease compared to animals receiving 4hLPS/CII/DCs alone or those in which only DXM was administered. Cytokine profile evaluation showed that CD4+ T cells from DXM/4hLPS/CII/DCs and 4hLPS/CII/DCs groups release higher IL-10 levels than those from mice receiving DXM alone or CIA mice. CD4+ T cells from all DC-treated groups showed less IL-17 release when compared to the CIA group. On the contrary, CD4+ T cells from DXM/4hLPS/CII/DCs and 4hLPS/CII/DCs groups released higher IFN-γlevels than those from CIA group.Conclusion. A combined treatment, including DXM preconditioning followed by an inoculation of short-term LPS-stimulated CII-loaded DCs, provides an improved strategy for attenuating CIA severity. Our results suggest that this benefit is driven by a modulation in the cytokine profile secreted by CD4+ T cells.


1985 ◽  
Vol 35 (2) ◽  
pp. 252-260 ◽  
Author(s):  
Nobuhiro Kaibara ◽  
Masahiro Morinaga ◽  
Chikafumi Arita ◽  
Takao Hotokebuchi ◽  
Kenji Takagishi

1986 ◽  
Vol 29 (9) ◽  
pp. 1131-1138 ◽  
Author(s):  
Marcia L. Bliven ◽  
Paul H. Wooley ◽  
Mark B. Pepys ◽  
Ivan G. Otterness

2007 ◽  
Vol 7 (10) ◽  
pp. 1360-1368 ◽  
Author(s):  
Mana Mitamura ◽  
Nami Nakano ◽  
Taeko Yonekawa ◽  
Lihua Shan ◽  
Toshihiko Kaise ◽  
...  
Keyword(s):  
T Cells ◽  

1981 ◽  
Vol 154 (3) ◽  
pp. 688-700 ◽  
Author(s):  
P H Wooley ◽  
H S Luthra ◽  
J M Stuart ◽  
C S David

A model of arthritis was established by the injection of type II collagen into mice. Only mice bearing the H-2q haplotype were susceptible to the disease. Susceptibility was further mapped by the use of recombinant strains on the Iq locus. Type II collagen arthritis was observed in the (resistant X susceptible) F1 cross. Mice strains were designated high, intermediate, or low responders with respect to the anti-type II antibody levels measured by radioimmunoassay. Arthritis-susceptible strains were all classified as high antibody responders. The clinical and histological appearance of type II collagen arthritis in the mouse indicates that it may be a good animal model for the investigation of various immunogenetic traits in rheumatoid arthritis.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4245-4245
Author(s):  
Alberto Grossi ◽  
Laura Pierdomenico ◽  
Laura Bonsi ◽  
Cosetta Marchionni ◽  
Francesco Alviano ◽  
...  

Abstract INTRODUCTION. Mesenchymal Stem Cells (MSC) have the ability to renew and differentiate into various lineages of mesenchymal tissue such as bone, cartilage, fat, muscle, etc. Moreover they are not immunogenic and display immunoregulatory activity in preclinical animal models. The aim of this study was to investigate whether dental pulp MSC (DPMSC) were able to differentiate toward osteogenesis, chondrogenesis and adipogenesis and express the characteristic immunomodulatory activity of MSC derived from known sources such as bone marrow. METHODS and RESULTS. We isolated MSC from dental pulp and bone marrow samples obtained from fully informed healthy donors. Flow cytometric analysis showed that either DPMSC or bone marrow MSC (BMMSC) expressed the membrane antigens SH2, SH3, SH4, CD29 and CD166, while CD 14, CD 34 and CD 45 were negative. Cell differentiation was evaluated after PDMSC and BMMSC were cultured in appropriate conditions. To evaluate adipogenesis after 2–3 weeks of culture the cells, containing neutral lipids in fat vacuoles, were fixed in 10% formalin and stained with fresh oil red-O solution. To demonstrate osteogenic differentiation, the cultures were fixed and subjected to alkaline phosphatase and von Kossa staining. For chondrogenic differentiation pellets were formalin fixed, embedded in paraffin, examined morphologically and immunostained for Type II collagen. We observed that either PDMSC and BMMSC were able to express clear osteogenic and chondrogenic differentiation as demonstrated by von Kossa staining and Type II collagen immunostaining respectively, but a lower number of adipocytes was obtained, according to morphology and red-oil staining, in DPMSC cultures. For proliferation assay cells were incubated overnight, then [methyl-3H] Thymidine was added (Time 0) and radioactivity followed for up to 15 days. DPMSC and BMMSc presented a very different behaviour in that DPMSC radioactivity had a steep increase from day 3 to 8, then decreasing at day 15, although still above the baseline value. On the contrary BMMSC radioactivity did not change significantly over the time of observation. Modulation of T Lymphocyte proliferation was studied by coculturing PHA stimulated T cells in the presence of MSC. Compared to cultures of T cells alone, the uptake of [methyl-3H] Thymidine was inhibited by 75%±3%(BMMSC)or 91%±4% (DPMSC). CONCLUSIONS: Dental pulp is a source of cells expressing the typical phenotype of MSC. Compared to BMMSC, DPMSC present a higher rate of proliferating cells (S-phase), and lower differentiation capabilities toward adipogenesis. These results suggest that BMMSC and DPMSCs are present at diverse differentiation stages, possibly not evidenced by phenotypic characteristics, and their plasticity in different experimental conditions should be further investigated. DPMSC are able to suppress stimulated T lymphocyte proliferation, as described for BMMSC. Therefore they are good candidates when modulation of T cell activity is required, as shown recently by Le Blanc (2003) in the treatment of GVHD in allogeneic transplantation setting.


1986 ◽  
Vol 19 (5-6) ◽  
pp. 320-322
Author(s):  
D. Westmacott ◽  
J. E. Hawkes ◽  
J. Wadsworth ◽  
C. H. Cashin ◽  
A. Cline ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document